The future of drug discovery.

"Great spirits have always encountered violent opposition from mediocre minds."

. . . Albert Einstein


Our Mission

COTI's mission is to apply our proprietary computer technologies to profile and identify commercially viable drug candidates at the earliest stage of pre-clinical drug development and thereby dramatically reduce the time line and cost of getting new drug therapies to market. COTI's platform technology is both revolutionary , and evolutionary! CHEMSASII™ is capable of adapting as new opportunities arise by being extremely flexible with a wide range of predictive modeling and profiling possibilities.

Our Vision

Our vision is to become a world leader in drug discovery by identifying, researching and developing novel compounds for patients with debilitating and life threatening disorders where inadequate treatments are currently available. We will be instrumental in saving thousands of lives by enabling accelerated development of new treatment options. We will decrease the risk of drug development through in silico modeling and increase shareholder value by developing these candidates to IND and beyond in a timely and cost-effective manner.

Our History

COTI was formed in 1999 with the intention of marketing its drug discovery and molecular screening technology to pharmaceutical and biotechnology companies. Other commercial opportunities that were identified included software design and support services for pharmaceutical companies looking to build in silico drug discovery in house. However, entrenched methodologies in the industry and internally developed drug development technologies within pharmaceutical companies made market penetration difficult. In 2000, COTI turned to developing its own molecule discoveries into drugs. Currently, three drugs have been patented, and two have been synthesized and tested in vitro and in vivo and several others are awaiting funds in order to patent and develop the compounds.